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The effect of increasing age on outcomes and type of treatment given to older women with ductal
carcinoma in situ (DCIS) was assessed. 646 women 60 years old (654 cases) receiving surgery for DCIS
at Memorial Sloan-Kettering Cancer Center between 2000 and 2007 (8 bilateral) had wide local excision
(WLE; 37%), WLE plus radiotherapy (WLEþ RT; 41%), or mastectomy (22%). 45%, 38%, and 16% of patients
60e69 years, 70e79 years, and 80 years, respectively, received WLEþ RT (P< 0.001) and 25%, 20%, and
13%, received mastectomy, respectively (P< 0.001). Age (P< 0.001), grade (P< 0.001), and necrosis
(P< 0.01) were highly associated with treatment. Four-year local recurrence was 3.6%. Overall local
recurrence differed by treatment (mastectomy, 0%; WLE, 5%; WLEþ RT, 4%; P< 0.00001) but not age. It is
possible to identify older women with DCIS in whom the risk of recurrence is acceptably low after WLE
alone. WLE alone may be a viable treatment option for select older women with DCIS.
 2010 Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Many breast-cancer physicians in the 21st century would agree
that the optimal treatment of ductal carcinoma in situ (DCIS) has yet
to be deﬁned. Despite the publication of several randomized stud-
ies1e7 over the past decade, two prospective studies8,9 and several
large retrospective studies10,11 documenting long-term outcomes
data on DCIS patients after various treatments, controversy over the
management still persists, as exempliﬁed by the wide variation in
practice patterns in DCIS in both Europe and the United States.12e16
Recent epidemiologic data reﬂect a dramatic increase in the
number of elderly women with cancer in the United States.17 The
number of women 65 years old diagnosed with DCIS in 2010 is
projected to be 25,000 andwill increase by 56% to 39,000 by 2030.18
These changes can be attributed to recent socioeconomic and public
health trends, such as the enlarging pool of older women,19,20 the
prevalenceof breast cancer in olderwomen, and increaseddetection
of DCIS secondary to greater availability and accessibility of
mammographic screening.21 Thus, the necessity of elucidating
treatment options and better understanding of factors that impactss under CC BY-NC-ND license.treatment choices becomes even more important in treating older
womenwith DCIS.
Several retrospective studies have suggested older women with
DCIS experience lower rates of local recurrence (LR) than younger
women.10,11,22,23 In the 1999 Memorial Sloan-Kettering Cancer
Center (MSKCC) analysis of women with DCIS treated with breast-
conserving surgery, Van Zee et al. reported lower 6 year actuarial LR
rates in older patients independent of histologic subtype, other
pathologic parameters, and the use of postoperative radiotherapy.11
In a study of long-term outcomes after breast-conserving surgery
and radiation for mammographically detected DCIS, Solin et al.
demonstrated that age >50 years was independently associated
with a lower risk of failure.10
The paucity of outcomes and treatment data speciﬁc to older
patients with DCIS, and the lack of uniform consensus among
physicians on the beneﬁt of radiation after breast-conserving
surgery in all DCIS patients, makes it difﬁcult to determine whether
excision alone may sufﬁce for elderly women with DCIS. With the
exception of one recently published prospective trial of wide exci-
sion alone in which the median age of the patients was 60 years,
women >60 years were under-represented in the randomized
studies investigating WLE with or without radiation1e5,24,25 and in
another prospective trial of wide excision alone8,9 in DCIS (Table 1).
Table 1
Representation of women 60 Years of Age in Studies of DCIS.
Study Study design Age group
(years)
Number of
patients 60
years old
Total number
of patients
(all ages)
NSABP B-171e3 RCT 60 294 818
EORTC4,5 RCT NR NR 1010
SweDCIS6 RCT 65 240 1067
58e64 264
UKCCR7 RCT 60e64 447 1701
65 168
Dana-Farber.8 Prospective 60 37 158
ECOG.9 Prospective 65e88 241 711
Solin et al.10 Retrospective 60 321 1003
Van Zee et al.11 Retrospective 40e69 103 171
70 39
ECOG¼Eastern Cooperative Oncology Group; EORTC¼European Organization for
Research and Treatment of Cancer; NR¼not reported; National Surgical Adjuvant
Breast and Bowel Project; RCT¼Randomized controlled trial; SweDCIS¼Swedish
Ductal Carcinoma In Situ; UKCCR¼United Kingdom Co-ordinating Committee on
Cancer Research.
Table 2
Patient and tumor characteristics.
Number %
Age (years)
60e69 401 62.1
70e79 191 29.6
80 54 8.4
Ethnicity
Caucasian 532 82.4
Hispanic 32 5.0
African-American 57 8.8
Other 25 3.9
Laterality at diagnosis
Right 316 48.9
Left 322 49.8
Bilateral 8 1.2
Grade
Low 109 16.7
Intermediate 312 47.7
High 229 35.0
Unknown 4 0.6
Necrosis
None 142 21.7
Focal 167 25.5
Moderate 195 29.8
Extensive 97 14.8
Unknown 53 8.1
Margin status
Negative 547 83.6
Positive 22 3.4
Close (<2 mm) 85 13.0
ER status
Negative 25 3.8
Positive 66 10.1
Unknown 563 86.1
ER¼estrogen receptor.
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older age in these studies.
In this study,we aimed to determine the impact of increasing age
and other clinicopathologic features on treatment patterns and
outcomes in olderwomenwith DCIS treatedwithin a contemporary
eraof surgical and radiation treatments,modernbreast imaging, and
rigorous microscopic margin assessment at a single large academic
center.
2. Materials and methods
Between January 2000 and December 2007, 779 women 60
years old underwent surgery for newly diagnosed pure DCIS at
MSKCC. After excluding 103 patients with a history of invasive
breast cancer, ﬁve with synchronous melanoma skin cancers, and
25 with a synchronous contralateral invasive breast cancer, 646
patients and 654 cases of DCIS remained.
WLE consisted of complete removal of known tumor. All slides
were evaluated by a team of dedicated breast pathologists for
histologic subtype, the presence of necrosis, nuclear grade, and
involvement of margins by DCIS. Microscopic size of the DCIS lesion
was not routinely evaluated. SLNB was generally performed in
“high-risk” patients in whom there was clinical or radiological
suspicion of invasion such as a palpable or mammographic mass,
pathology suspicious but not diagnostic for invasion, or extensive
disease requiring mastectomy. The most common reason for SLNB
was multicentric disease requiring mastectomy. Post-excision
mammograms were performed in patients presenting with suspi-
cious calciﬁcations and receiving WLE.
Nuclear grade was categorized as low, intermediate, or high,
based on the Lagios nuclear grading system.26 Necrosis was deﬁned
as the presence of a central zone of necrotic debris with karyor-
rhexis, and categorized as minimal, moderate, or extensive. ER
receptor status was not routinely evaluated. Although microscopic
margin evaluation was performed on every case, exact margin
width and number of ducts involved by DCIS at the margin was not
routinelymeasured. Margins were categorized as negative, close, or
positive. Close margins were deﬁned as the presence of duct(s)
involved by DCIS 2 mm from the inked surface of the specimen.
Adjuvant radiationwas deliveredwith two tangential beams. For
the 127 patients who received radiation at an outside institution,
treatment summaries documenting the dose and fraction size were
obtained.A sequential boost to the lumpectomycavitywasdelivered
to 60% (159/264) of patients who received whole breast radiation.
No patients received cytotoxic chemotherapy. 17% receivedhormonal therapy, consisting of mostly tamoxifen, although letro-
zole, anastrozole, and raloxifene were also utilized.
Follow-up consisted of annual mammograms, routine interval
history, and physical examinations, commencing from the date of
deﬁnitive surgery (excision or re-excision) for DCIS. LR was deﬁned
as the subsequent occurrence of biopsy-proven invasive or intra-
ductal breast cancer in the treated breast and/or regional lymph
nodes. Time to LR was calculated from the date of the deﬁnitive
surgery to the date of histologically proven recurrence.
The chi-square testwas used to examine differences between the
distribution of characteristics among age and treatment groups. An
ordinal logistic regression model was used for multivariate analysis
of predictors of treatment received. We reported the odds ratios
with their 95% conﬁdence intervals. KaplaneMeier methods were
utilized to calculate time to local recurrence and overall survival.
Univariate associations between clinicopathologic variables and
recurrences were assessed using the log rank test. Multivariate
analysis of recurrence couldnotbeperformeddue to a small number
of events.
3. Results
Table 2 details patient and tumor characteristics of the 646
patients. The median age at diagnosis was 67 years (range, 60e88
years). Eighty-seven percent of patients presented with mammo-
graphically detected disease without a palpable mass. Abnormal
mammogram ﬁndings included suspicious calciﬁcations in 73%,
mass in 12%, and both in 3%. Intermediate- or high-grade DCIS
together represented 83% of lesions. Necrosis was identiﬁed in 459
(70%) cases, 292 of which were moderate or extensive. Margins
Table 4
Clinicopathologic and treatment characteristics by treatment type.
WLE
(n¼240)
WLEþ RT
(n¼266)
Mastectomy
(n¼148)
P value
Number % Number % Number %
Age (years)
60e69 120 50% 184 69% 103 70% <0.0001
70e79 81 34% 73 27% 38 26%
80 39 16% 9 3% 7 5%
Ethnicity
Caucasian 208 87% 220 83% 111 75% 0.12
Hispanic 8 3% 14 5% 10 7%
African-American 16 7% 24 9% 17 11%
Other 8 3% 8 3% 10 7%
Grade
Low 68 28% 28 11% 13 9% <0.0001
Intermediate 120 50% 126 47% 66 45%
High 50 21% 110 41% 69 47%
Unknown 2 1% 2 1% 0 0%
Necrosis
None 82 34% 46 17% 14 9% <0.0001
Focal 62 26% 53 20% 52 35%
Moderate 52 22% 98 37% 45 30%
Extensive 22 9% 51 19% 24 16%
Unknown 22 9% 18 7% 13 9%
Margin status
Negative 195 81% 209 79% 142 96% 0.0001
Positive 10 4% 11 4% 1 1%
Close (<2 mm) 35 15% 46 17% 4 3%
Unknown 0 0% 0 0% 1 1%
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3%. ER status was unknown in 86% of patients, as receptor testing
was not routinely performed. Ten percent of patients were ER
positive and 4% were ER negative.
Treatment characteristics are outlined in Table 3. Of 646 patients,
240 (37%) receivedWLEalone, 266 (41%)WLEwith radiation, and148
(22%) mastectomy. Eight patients had bilateral DCIS. Approximately
one-third (32%) of patients underwent axillary lymph-node evalua-
tion, either SLNB alone in 192 (29%), SLNB followed by axillary
dissection in 16 (2%), or axillary dissection only in 2 (0.3%). Radiation
was delivered to thewhole breast in 265 (41%) patients after breast-
conserving surgery. Sixty percent (159/265) of patients receiving
whole breast radiation also received a boost to the lumpectomy
cavity. Themediandose andnumberof fractionsof patients receiving
whole breast radiation was 5500 cGy (range, 4240e6840 cGy) and
28 fractions, respectively. One patient received partial breast radio-
therapy to a dose of 3400 cGy. The vastmajority (83%) of patients did
not receive hormonal therapy.
Table 4 represents the clinicopathologic characteristics of all 654
cases stratiﬁed by treatment type. A signiﬁcantly higher proportion
of patients who received mastectomy were 60e69 years old (70%),
compared with those 70e79 and 80 years (26% and 5%,
P< 0.0001). Similarly, a signiﬁcantly higher proportion of patients
who received radiation following WLE were 60e69 years (69%),
compared with 70e79 and >80 years (27% and 3%, P< 0.0001). As
the amount of necrosis increased, so did the proportion of patients
receiving mastectomy or radiation in addition to WLE (P< 0.0001).
Patients with high-grade tumors were also more likely to receive
post-excision radiation or mastectomy (P< 0.0001). Other clinico-
pathologic variables stratiﬁed by age group are seen in Table 5. A
signiﬁcant trendwas seen in the use of radiation andmastectomy in
the 60e69 years age group (45% and 25%) and 70e79 years (38% and
20%) age group, compared with the 80 age group (16% and 13%,
P< 0.0001). All other examined variables did not correlate signiﬁ-
cantly with age.Table 3
Treatment characteristics.
Number %
Treatment type
WLE 240 37%
WLEþ RT 266 41%
Mastectomy 148 22%
Lymph-node evaluation
Not evaluated 444 67.9%
SLNB only 192 29.4%
AD only 2 0.3%
SLNBþAD 16 2.4%
Hormones
No 543 83.0%
Yes 111 17.0%
Radiation therapy
No 388 59.3%
Yes 266 40.7%
Boost
No 74 11.3%
Yes 159 24.3%
Unknown 33 5.0%
No RT 388 59.3%
Radiation volumes
Partial breast 1 0.2%
Whole breast 265 40.5%
No RT 388 59.3%
AD¼axillary dissection; RT¼radiotherapy; SLNB¼sentinel lymph node biopsy; WLE,
wide lesion excision.In an ordinal logistic regression model, age group (P< 0.001),
grade of tumor (P< 0.001), and necrosis (P¼0.01) were found to be
statistically signiﬁcant predictors of treatment type when
comparing WLE, WLEþ RT, and mastectomy (Table 6). Younger age
was correlated to more aggressive treatment. Similarly, the higherTable 5
Clinicopathologic and treatment characteristics by age group.
60e69 Years
(n¼407)
70e79 Years
(n¼192)
80 Years
(n¼55)
P value
Number % Number % Number %
Ethnicity
Caucasian 328 81% 183 85% 48 87% 0.35
Hispanic 20 5% 8 4% 4 7%
African-American 38 9% 16 8% 3 5%
Other 21 5% 5 3% 0 0%
Grade
Low 58 14% 42 22% 9 16% 0.28
Intermediate 204 50% 84 44% 24 44%
High 143 35% 64 33% 22 40%
Unknown 2 0% 2 1% 0 0%
Necrosis
None 85 21% 45 23% 12 22% 0.39
Focal 95 23% 54 28% 18 33%
Moderate 132 32% 52 27% 11 20%
Extensive 61 15% 29 15% 7 13%
Unknown 34 8% 12 6% 7 13%
Margin status
Negative 351 86% 154 80% 41 75% 0.2
Positive 12 3% 8 4% 2 4%
Close (2 mm) 43 11% 30 16% 12 22%
Unknown 1 0% 0 0% 0 0%
Treatment type
WLE 120 29% 81 42% 39 71% <0.0001
WLEþ RT 184 45% 73 38% 9 16%
Mastectomy 103 25% 38 20% 7 13%
RT¼radiotherapy; WLE¼wide local excision.
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aggressive the treatment received. However, when comparing the
WLE vsWLEþ RT groups alone, only age and grade were associated
with the receipt of radiation. The older the age group, the less likely
postoperative radiation was received (P< 0.0001, Table 6). The use
of postoperative radiation after WLE was also associated with
intermediate- or high-grade tumors (P< 0.0001). Margin status
and necrosis were not found to be statistically signiﬁcant predictors
of treatment received when only the WLE and WLEþ RT groups
were compared.
Median follow-up was 54 months (range, 6e112 months) for the
646 cases. Median follow-up for each treatment group was as
follows: mastectomy, 53 months, WLEþ RT, 52 months, WLE 49
months. Four-year overall survival for the entire group was 95.4%
(Fig.1a) and4-year local control ratewas 96.4% (Fig.1b),with 31 local
recurrences. Twenty-twoof the local recurrenceswereDCIS andnine
were invasive. Differences in 4-year recurrence rates by treatment
type were statistically signiﬁcant when all three treatment groups
(mastectomy, WLE, and WLEþ RT) were compared (P¼0.005,
Fig. 2a). However, there was no statistically signiﬁcant differences
between 4-year recurrence rates when only WLE vs WLEþ RT were
compared (95% and 96%, respectively; P¼0.66, Fig. 2b).
Among the 240 patients who received WLE alone, 16 had local
recurrences (10 DCIS, six invasive) (Fig. 3). Among the 266 patients
who received WLE and radiation, there were 15 local recurrences
(12 DCIS, three invasive). None of the 148 patients who received
mastectomy experienced a recurrence at her last follow-up prior to
data analysis. There were 20 LRs (15 DCIS, ﬁve invasive) among the
401 patients 60e69 years, six LRs (four DCIS, two invasive) among
the 191 patients 70e79 years, and ﬁve LRs (three DCIS, two inva-
sive) among the 54 patients 80. Four-year recurrence-free
survival did not differ by age and was 97%, 98%, and 96%, respec-
tively (P¼0.07). Associations between margin status, necrosis, and
grade and the risk of recurrence in patients who received WLE vs
WLEþ RT were not statistically signiﬁcant.Table 6
Multivariate model of predictors of treatment.
Odds ratio (95% CI) P value
All treatment groups
Age (years)
60e69 Reference <0.0001
70e79 0.66 (0.47e0.91)
80 0.17 (0.09e0.32)
Grade
Low Reference <0.0001
Intermediate 1.77 (1.08e2.88)
High 3.41 (1.96e5.94)
Unknown 0.80 (0.11e6.03)
Necrosis
None Reference 0.01
Minimal/Focal 2.34 (1.45e3.78)
Moderate 1.87 (1.15e3.05)
Extensive 1.81 (1.01e3.24)
Unknown 1.86 (0.98e3.55)
Excluding mastectomy group
Age (years)
60e69 Reference <0.0001
70-79 0.65 (0.43e0.99)
80 0.12 (0.05e0.28)
Grade
Low Reference <0.0001
Intermediate 2.42 (1.43e4.10)
High 5.32 (2.96e9.56)
Unknown 1.17 (0.14e9.78)4. Discussion
Selecting the appropriate treatment for DCIS is a clinical quan-
dary that has resulted in substantial variation in both the perception
of risk and management of the disease among breast-cancer
physicians.27 Although treatments for DCIS do not impact survival,
uncertainty in choosing among treatment options is magniﬁed by
competing comorbidities in older women. Data from multiple
randomized trials1e7 demonstrate a reduction in local recurrence
with the addition of radiation after lumpectomy. However, without
data that can reliably identifya groupwhose risk of recurrence is low
enough to justify withholding radiation, many patients, including
elderly women, are often overtreated to achieve the risk reduction
seen when adding radiation.
Currently, little is known regarding the clinical, pathologic, and
patient-driven factors that shape treatment decisions in older
women with DCIS. The signiﬁcance of the latter was recently
highlighted in a large SEER-Medicare study of 1125 patients
(including those>79 years) with DCIS and invasive breast cancer,28
which aimed to determine the role of age and age-related factors in
surgical decision-making for breast-cancer treatments. Older
women with DCIS were found to choose mastectomy over breast-
conserving treatment in DCIS equally compared with younger
women, but used less knowledge to decide. Larger tumor size,
lower education level, and number of surgeons consultedFig. 1. Outcomes for entire cohort: 4-year overall survival¼95.4%, cause-speciﬁc
survival¼100% and 4-year recurrence-free survival¼96.4%.
Fig. 2. a. Local recurrence by WLERT or mastectomy. Four-year recurrence-free
survival: WLE, 95%; WLEþ RT, 96%; mastectomy 100%. b. Local recurrence by
WLE RT. Four-year recurrence-free survival: WLE, 95%; WLEþ RT, 96%.
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sion, and comorbidities did not.
In our study, age was highly associated with aggressiveness of
treatment. Also, increasing extent of necrosis and grade correlated
with the addition of radiation to WLE and mastectomies, both ofFig. 3. Recurrence-free survival by age group. 4Y-RFS: 97% (60e69 years old), 98%
(70e79 years old), 96% (>80 years old).whichwere performedmore frequently in patients 60e69 years old
or with tumors with extensive necrosis or high-grade histology.
However, unlike the above SEER registry study, we did not factor in
the impact of comorbidities, in elderly patients, in whom morbid-
ities from other co-existing illnesses may transcend the small risk
of death due to DCIS and drive treatment choice.
AnLR rateof3.6%at4yearswas reported for the entirepopulation,
comparable to 3%e6% 5-year recurrence rates reported in studies of
breast-conserving surgery with radiation,10,29 and lower than the
9%e16% 5-year recurrence rates seen with surgery alone.22,29 There
was no difference between recurrence rates by age group or by
treatment received. Considering thehighproportion (83%)ofpatients
in the studywhopresentedwitheither intermediate-orhigh-nuclear
grade lesions, the low 4-year recurrence rate is encouraging, as
higher-grade tumorsare typically prognostic forearly rather than late
recurrence risk,30 and wewould therefore have expected the bulk of
local recurrences from higher-grade tumors to manifest themselves
within the median follow-up period of the study.
The beneﬁt of radiation added to breast-conserving surgery has
been clearly documented in a SEER-cohort based study of 3409
patients 66 years old with DCIS treated with breast-conserving
surgery, with nearly half the patients receiving postoperative radio-
therapy.12 The primary outcome was a second breast-cancer event,
including either salvage mastectomy or subsequent breast cancer.
High-riskwas deﬁned as the presence of at least one of the following
features: age 66e69 years, tumor size >2.5 cm, comedo histology,
and/or high-grade. The addition of radiation to WLE was found to
lower the 5-year risk of a second breast-cancer event in both the low
risk (8% forWLEvs 1% forWLEþ RT, P< 0.001) andhigh-risk (14% for
WLE vs 4% for WLEþ RT, P< 0.001) groups.
Several explanations may account for the observed differences
between these population-based studies and our results. Among
other well-described risk factors for local recurrence in DCIS such as
histologic subtype, presence of necrosis, grade, and young age,5,31,32
margin status has been described as the most important of them
all.33 Patient-speciﬁc data on margins and amount of necrosis were
not reported in the SEER study, as this information was not readily
available through Medicare claims data and was therefore not
factored into the categorization of low- versus high-risk groups in
the study. Moreover, population-based studies theoretically reﬂect
the clinical practice patterns in a diverse community setting. It is
possible that there may have been a wide variability in margin
evaluation and status, subsequently biasing physicians towards
recommending radiation in patients with involved margins and
thereby overestimating the beneﬁt of radiation.
In contrast, the patients in our study were subjected to the
practice patterns of a single, large academic institution, where
margin status was regularly evaluated by dedicated breast pathol-
ogists and patients were treated by one of a group of 11 breast
surgeons who share relatively compatible treatment philosophies
on the signiﬁcance of obtaining clearmargins inDCIS, as reﬂected by
the few patients with positive (3%) or close (13%) margins in the
study and the even distribution of positive or close margins among
the WLERT groups (Table 2). The high percentage of patients with
negative margins in our study may have reduced the observed
potential beneﬁts of radiation. An association between margin
statusand recurrence rates inpatients treatedwithWLERTwasnot
seen, likely due to the small sample size in each subgroup. Again,
secondary to the low total number of events, this study with rela-
tively short follow-up lacked the statistical power required to detect
a signiﬁcant beneﬁt conferred by radiation.
Several shortcomings of the study deserve mention. We were
unable to investigate whether re-excision rates inﬂuenced treat-
ment received. The number of re-excisions performed per patient
was not quantiﬁed, but it has been shown thatmultiple re-excisions
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recurrence in DCIS.34 Although the number of re-excisions has been
associated with the greater likelihood of mastectomy in young
women,35 the impact in the older population is largely unknown. In
addition, neither pathologic size of the tumor nor the extent of
calciﬁcations correlatingwith theDCIS lesion onmammogramwere
routinely measured at our institution, because quantifying the
pathologic size of the DCIS lesion is technically difﬁcult and calciﬁ-
cations seenonmammogramcanunderestimate the truepathologic
extentof the lesion. Tumor sizemaynotpredict LR inDCIS, as a linear
relationship was not identiﬁed in either the National Surgical
Adjuvant Breast and Bowel Project (NSABP) B-17 or European
Organization for Research and Treatment of Cancer (EORTC)
randomized trials of WLERT for DCIS.1,4 Although we would
anticipate that large tumor size could be a surrogate for extensive
disease requiring mastectomy, it would have been useful to assess
whether tumor size impacted the receipt of radiation after WLE.
Lastly, our median follow-up period is short, considering the long
natural history of DCIS.
It is critical to interpret these results within the framework of the
inherent biases that accompany this retrospective study. Well-
established pathologic risk factors for recurrence such as extensive
necrosis and high-grade tumors were more representative in
patients in theWLEþ RTandmastectomygroups than theWLEalone
group, which could explain the similarity in short-term outcomes
between the three treatment groups. Rather than concluding that
postoperative radiation does not make a difference in this patient
population, our studydemonstrates that it is possible for clinicians to
select older womenwith low risk features who dowell in the short-
termwithWLE alone. Although the prospect of omitting radiation in
this deﬁned population is appealing, it clearly requires validation in
aprospective setting andcollectionof long-termoutcomesdataprior
to acceptance as routine practice.
5. Conclusions
Recent advancements in radiation have afforded more options
to older patients with DCIS receiving radiation, including the
omission of a boost, the use of hypofractionated radiation regimens,
and partial breast irradiation, all of which can subsequently reduce
the costs, time, and morbidity of adjuvant radiation. A deeper
understanding of molecular features unique to older women with
DCIS36 that are predictive for the development of invasive disease,
as well as tools that elucidate the decision-making process of older
women with breast cancer, will aid us greatly in the further
reﬁnement of our treatment options for this unique population.
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